OA11376A - Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. - Google Patents
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. Download PDFInfo
- Publication number
- OA11376A OA11376A OA1200000133A OA1200000133A OA11376A OA 11376 A OA11376 A OA 11376A OA 1200000133 A OA1200000133 A OA 1200000133A OA 1200000133 A OA1200000133 A OA 1200000133A OA 11376 A OA11376 A OA 11376A
- Authority
- OA
- OAPI
- Prior art keywords
- thieno
- phenyl
- indol
- pyrimidin
- amine
- Prior art date
Links
- 0 *c1cc(nccc2Cl)c2[s]1 Chemical compound *c1cc(nccc2Cl)c2[s]1 0.000 description 3
- TWEQNZZOOFKOER-UHFFFAOYSA-N COC(c([s]cc1)c1N)=O Chemical compound COC(c([s]cc1)c1N)=O TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- GYQUXKQLCNFKQT-UHFFFAOYSA-N Clc1c2[s]ccc2ncc1 Chemical compound Clc1c2[s]ccc2ncc1 GYQUXKQLCNFKQT-UHFFFAOYSA-N 0.000 description 1
- DKGYESBFCGKOJC-UHFFFAOYSA-N Nc1c[s]cc1 Chemical compound Nc1c[s]cc1 DKGYESBFCGKOJC-UHFFFAOYSA-N 0.000 description 1
- AACVULYSNJAKEQ-UHFFFAOYSA-N O=C1c([s]cc2)c2NC=C1 Chemical compound O=C1c([s]cc2)c2NC=C1 AACVULYSNJAKEQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Claims (30)
- -67- 011376 5 CLAIMSor a pharmaceuticalty acceptable sait or hydrate thereof, wherein:wherein X1 is N or CH; 10 R1 is H, Ci-C6 alkyl or -C(O)(C,-C6 alkyl); R2 is Ce-Cw aryl or 5-13 membered heterocyclic, wherein said R2 groups are optionallysubstituted by 1 to 5 R5 substituents, each R3 is independently selected from H, -C(O)OR9, and Ci-C6 alkyl wherein said alkyl isoptionally substituted by 1 to 3 R5 groups; 15 R4 is R3, -OR9, or -NR9R10; each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy,trifluoromethyl, azido, -C(O)R8. -C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7,-NR®R7. -OR9, -SO2NR6R7, C,-C6 alkyl, -(CH2)iO(CH2)qNR6R7, -(CH2),O(CH2)„OR9. -(CH2),OR9,-S(O)j(Ci-C6 alkyl), -(CH2),(C6-C10 aryl), -(CH2),(5-10 membered heterocyclic), -C(O)(CH2),(C6- 20 C10 aryl), -(CH2),O(CH2)j(C6-C50 aryl), -(CH2),O(CH2)q(5-10 membered heterocyclic). -C(O)(CH2)t(5-10 membered heterocyclic), -(CH2)jNR7(CH2)qNR6R7, -<CH2)iNR7CH2C(O)NR6R7,-(CH2)jNR7(CH2)qNR9C(O)R8, -(CH2)iNR7(CH2),O(CH2)qOR9. -(CH2)jNR7(CH2)„S(O)1(C,-C6 alkyl).-(CH2)jNR7(CH2),R6. -S02(CH2)t(C6-C1o aryl), and -SO2(CH2),(5-10 membered heterocyclic), , wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6, q is an integer 25 ranging from 2 to 6, the -(CH2)q- and -(CH2)t- moieties of the foregoing Rs groups optionallyinclude a carbon-carbon double or triple bond where t is an integer between 2 and 6, and thealkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R8,-C(O)OR8, -OC(O)R8, -OC(O)OR8, -NReC(O)R7, -C(O)NR6R7, -<CH2),NR6R7, CrC6 alkyl, 30 -(CH2),(C6-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH2),O(CH2)„OR9, and -(CH2),OR9. wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6; each R6 and R7 is independently selected from H, C,-C6 alkyl, -(CH2),(C6-Ci0 aryl),-(CH2),(5-10 membered heterocyclic). -(CH2),O(CH2)qOR9. and -{CH2),OR9, wherein t is aninteger ranging from 0 to 6 and q is an integer ranging from 2 to 6, and the alkyl, aryl and 35 heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted by 1 to 3substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R8, -68- 011376 10 15 20 25 30 -C(O)0R8. -CO(O)R8, -0C(O)OR8, -NR9C(O)Rw, -C(O)NR9Rw, -NR9Rw, c,-c6 alkyl,-(CH2),(C6-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH2),O(CH2)qOR9, and -(CH2),OR9.wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6, with theproviso that where R6 and R7 are both attached to the same nitrogen, then R6 and R7 are notboth bonded to the nitrogen directly through an oxygen; each R8 is independently selected from H, C,-Cw alkyl, -(CH2),(C6-C,o aryl), and-(CH2),(5-10 membered heterocyclic), wherein t is an integer ranging from 0 to 6; each R9 and R10 is independently selected from H and CrC6 alkyl; R" is H, CrC6 alkyl, -C(O)NR®R9, -C(O)(C6-C,0 aryl), -{CHjMCe-Cw aryl), or -<CH2),(5-10membered heterocyclic), wherein t is an integer ranging from 0 to 6, wherein said R11 groups,otherthan H, are optionally substituted by 1 to 5 R5 groups; and, R12 is H, C,-C6 alkyl, -C(O)(Ci-Cs alkoxy), -8(0)/0,-06 alkyl), -SO2(CH2),(C6-CW aryl),-(CH2),(Ce-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH2),O(CH2)qOR9, or -(CH2),OR9,wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6 and q is an integerranging from 2 to 6.
- 2- Diethylaminomethyl-4-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenol;5-Methyl-1-[4-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-1,2-dihydro-pyrazol-3- one; [4-(4,5-Dichloro-imidazol-1-yl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 10 (6-Phenyl-thieno[3,2-dlpyrimidin-4-yl)-[4-(3-trifluoromethyl-pyrazol-1 -yl)-phenyl]-amine; (4-(4-Methyl-pipera2in-1-yl)-phenyl]-(6-phenyl-thieno{3I2-dÎpyrimidin-4-yl)-amine;[4-<4-Methyl-piperidin-1-yl)-phenyl]-(6-phenyl-thienof3,2-d]pyrimidin-4-yl)-amine; l-{4-(6-Phenyl-thienol3,2-d]pyrimidin-4-ylamino)-phenyl]-1H-tetrazole-5-thiol; 3- (6-PhenyHhieno[3,2-d]pyrimidin-4-ylamino)-benzenesulfonamide; 15 (2-Methyl-benzothiazol-6-yl)-(6-Pheriyl-thieno(3,2-d]pyrimidin-4-yl>-amine; [4-(Morpholine-4-sulfonyl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; (3,5-Dimethyl-4-(thiophen-3-yimethoxy)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; [4,5-Dimethoxy-2-(1H-tetrazol-5-yl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- 20 amine; 5- [4-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-oxazolidine-2,4-dione;1-Ethyl-5-<6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1,3-dihydro-indol-2-one; 6- (6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-3H-benzooxazol-2-one;Dibenzothiophen-4-yl-(6-phenyt-thieno[3,2-d]pyrimidin-4-yl)-amine; 25 N-(6-Pheny1-thieno[3,2-d]pyrimidin-4-yl)-N'-p-tolyt-benzene-1,2-diamine; (2-Furan-2-yl-1-methyl-1H-benzoimidazol-5-yl)-{6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; 5-(6-Phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-benzo[b]thiophene-2-carbonitrile; (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-{2-pyridin-4-yl-1H-benzoimidazol-5-yl)-amine; 30 [4-( 1 -Methyl-1 H-imidazol-2-ylsulfanyl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-[4-(pyridin-2-yloxy)-phenyl]-amine; [4-(5-Methyl-tetrazol-1-yl)-phenyl]-{6-phenyl-thieno[3,2-d]pyrimidin-4-yf)-amine; 1-[3-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamÎno)-phenyl]-1H-tetrazole-5-thiol; 35 4-[4-(6-Phenyl-thieno[3,2-dJpyrimidin-4-ylamino)-phenylamino]-phenol; [3-{3-Methyi-4,5-dihydro-pyrazol-1-yl)-phenyI]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)- amine; [6-{4-Fluoro-phenyl)-thieno[3,2-d]pyriniidin-4-yl]-(1H-indol-5-yl)-amine; Benzo[1,2,3]thiadiazol-6-yl-(6-phenyl-thieno[3,2-<i]pyrimidin~4-yl)-amine; 40 and the pharmaceutically acceptable salts and hydrates of the foregoing compounds.2-Amino-3-(3-{4-(4-( 1 H-indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-3H- imidazol-4-yl)-propionic acid methyl ester, 3-{4-[4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-€-yl]-benzylamino}-2,2-dimethyl- propan-1-ol; (9-Ethyl-9H-carbazol-3-yl)-(6-phenyl-thienoI3,2-d]pyrimidin-4-yl)-amine; 10 [1 -(2-Diethylamino-ethyl)-1 H-indol-5-yl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; [1-(3-Diethylamino-propyl)-1H-indol-5-yl]-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;(2-Bromo-thieno(3,2-b]pyridin-7-yl)-(1 H-indol-5-yl)-amine; [6-(4-Aminomethyl-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine;2. A compound of claim 1 wherein said compound is a compound of formula 1wherein R11 is -(CH2),(C6-Cio aryl) or -(CH2),(5-10 membered heterocyclic), wherein t is aninteger ranging from 0 to 6, wherein said R11 groups are optionally substituted by 1 to 5 Rs groups.
- 3-Hydroxy-2-(4-[4-(1H-indol-5-yiamino)-thieno[3t2-dJpyrimidin-6-yl]-benzylamino}- 15 propionic acid methyl ester; Furan-2-yl-(4-{4-[4-( 1 H-indol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzyl}-piperazin-1 -yl)-methanone; [6-(4-Dimethylaminomethyl-phenyl)-thieno[3I2-d]pyrimidin-4-yl]-{1H-indol-5-yl)-amine; 2-({4-(4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-methyl-amino)- 20 éthanol; (1 -{4-(4-( 1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl)-pynOlidin-2-yl)-methanol; 2-(2 -(4-(4-(4-( 1 H-lndol-5-yIamino)-thieno[3,2-d]pynmidin-6-y1]-benzyl}-piperazin-1 -yl)-ethoxyj-ethanol; 25 4-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzoic acid; (3-Methyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; ( 1 H-lndol-5-yl)-(2-methyl-6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;N-(4-Methoxy-phenyl)-N'-(2-methyl-6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-benzene-1,4- diamine; 30 N-(2-Benzyloxy-ethyl)-N'-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 5-(6-Phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-1 H-indole-3-carbaldehyde;(3-Bromo-1H-indol-5-y!)-(6-phenyl-thieno(3,2-d]pyhmidin-4-yi>-amine; N-( 1 H-lndol-3-ylmethyl)-N'-(6-phenyl-thteno{3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;N-(6-Bromo-thieno(3,2-d]pyrimidin-4-yl)-N,-(4-methoxy-phenyl)-benzene-1,4-diamine; 35 N-(4-Methoxy-phenyl)-N*-[6-(2-nitro-phenyl)-thieno{3,2-dlpyrimidin-4-yll-benzene-1,4- diamine; N-(4-Methoxy-phenyl)-N‘-[6-(4-methoxy-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-benzene-1,4-diamine; N-(4-Methoxy-phenyl)-N’-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4- 40 diamine; -75- Π Ί ή 2 7 aυ ι ιό/Ο 5 N-(4-Methoxy-phenyl)-N'-Î6-{6-methoxy-pyridin-3-yl)-thieno[3,2-d]pyrimidin-4-yl]- benzene-1,4-diamine; (1H-lndol-5-yl)-[6-(4-thiomorpholin-4-ylmethyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl]- amine; 6-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-benzothiazole-2-thioi; 10 N-(4-Methoxy-phenyl)-N’-thieno[3,2-d]pyrimidin-4-yl-benzene-1,4-diamine; N-(2-Methoxy-phenyl)-N’-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine,N-(6-Phenyl-thieno(3,2-d]pyrimidin-4-yl)-N'-o-tolyl-benzene-1,4-diamine;N-(6-Phenyl-thieno(3,2-d]pyrimidin-4-yl)-N'-p-tolyl-benzene-1,4-diamine;N-(3.4-Dimethoxy-phenyl)-N'-{6-phenyl-thienol3,2-d]pyrimidin-4-yl)-benzene-1,4- 15 diamine; N-(6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-N‘-(3,4,5-trimethoxy-phenyl)-benzene-1,4-diamine; N-{6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-N'-m-tolyl-benzene-1,4-diamine;N-(4-Chloro-phenyl)-N‘-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 20 (1H-lndol-5-yl)-[6-(6-methoxy-pyridin-3-yl)-thienoI3,2-d]pyrimidin-4-yl]-amine; N-(4-dimethylamino-phenyl)-N'-{6-phenyl-thienol3,2-d]pyrimidin-4-yl)-benzené-1,4- diamine; N-(3-Methoxy-phenyt)-N'-(6-phenyl-thieno{3,2-d]pyrimidin-4-yJ)-benzene-1,4-diamine; ( 1,3-Dibromo-1 H-indol-5-yl}-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 25 (6-Chloro-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yi)-amine; |5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indoi-3-yl]-methanol; (6-Phenyl-thieno{3,2-d]pyrimidin-4-yl)-{3-[(3-pyrazol-1-yl-propylamino)-methyl]-1H-indol- 5-yl}-amine; U5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indol-3-ylmethyl]-amino}-acetic acid 30 methyl ester, 2-{[5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indol-3-ylmethyI]-amino}-ethanol;5-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-1H-indole-3-carbaldehyde oxime;(3-Methyliminomethyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;[3-{2-Nitro-vinyl)-1H-indol-5-yl]-<6-phenyl-thieno[3,2-d]pyrimidin-4-yi)-amine; 35 4-{4-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenylamino]-phenol;3. A compound of claim 2 wherein R11 is phenyl or pyridyl, wherein said phenyl andpyridyl are optionally substituted by 1 to 5 R5 groups.
- 4-Methyl-N-[4-(6-phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-phenyl]-benzenesulfonamide;N-Phenyl-N'-(6-phenyl-thieno{3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 35 (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-(2H-pyrazol-3-yl)-amine; ( 1 H-Indazol-6-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;N,N-Dimethyl-N'-(6-phenyl-thieno{3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;(2,3-Dimethyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;N-Ethyl-N'-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 40 [4-(1H-lndol-5-ytamino)-thieno[3,2-d]pyrimidin-6-yl]-phenyl-methanone; ( 1 H-lndol-5-yl)-(6-p-tolyl-thieno[3,2-d]pynmidin-4-yt)-amine; -70- 011376 5 (5-Furan-2-yl-2H-pyrazol-3-yl)-thieno[3,2-d]pyrimidin-4-yl-amine; Thieno[3,2-d]pyrimidin-4-yl-(5-thiophen-2-yl-2H-pyrazol-3-yl)-amine; (5-(4-Chloro-phenyl)-2H-pyrazol-3-yl]-thienoI3,2-d]pyrimidin-4-yl-amine; (2H-Pyrazol-3-yl)-thieno(312-d]pyrimidin-4-yl-amine; Thieno[3,2-d]pyrimidin-4-yl-(5-p-tolyl-2H-pyrazol-3-y1)-amine; 10 4-(4-(1 H-Indol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl}-benzaldehyde; (6-(4-Chloro-phenyl)-thieno(3t2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [6-(4-Fluoro-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; (1H-lndol-5-yl)-(6-thiophen-3-yl-thieno(3,2-d]pyrimidin-4-yl)-amine; 2-(3-(4-Chloro-phenyl)-5-(thieno(3,2-d]pyrimidin-4-ylamino)-pyrazol-1-yl]-ethanol; 15 (1 H-lndol-5-yl)-[6-(4-trifluoromethyl-phenyl)-thieno[3,2-d]pynmidin-4-yl]-amine; (1H-lndol-5-yl)-(6-(4-methylsulfanyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl}-arnine; (1H-lndol-5-yl)-(6-(3-nitro-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine; (6-(3-Chloro-4-fluoro-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [5-(4-Methoxy-phenyl)-2H-pyrazol-3-yll-thieno[3,2-d]pyrimidin-4-yl-amine; 20 4-[5-(Thieno[3,2-d]pyrimidin-4-ylamino)-1 H-pyrazol-3-yl]-benzoic acid methyl ester, (5-Methyl-2H-pyrazol-3-yl)-thieno(3,2-d]pyrimidin-4-yl-amine; 5-(6-Phenyl-thieno(3,2-d]pyrimidin-4-ylamino)-1 H-indole-2-carboxylic acid ethyl ester;(6-Benzofuran-2-yl-thieno[3,2-d]pyrimidin-4-yl)-( 1 H-indol-5-yl)-amine;Thieno[3,2-d]pyrimidin-4-yl-(5-m-tolyl-2H-pyrazol-3-yl)-amine; 25 (5-(3-Chloro-phenyl)-2H-pyrazol-3-yl]-thieno[3,2-d]pyrimidin-4-yl-amine; [6-(4-Ethyl-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; 4-(4-( 1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzoic acid methyl ester;4-[5-(Thieno[3,2-d]pyrimidin-4-ylamino)-1 H-pyrazol-3-ylJ-benzoic acid; ( 1 H-lndol-5-yl)-(6-thiophen-2-yl-thieno[3,2-d]pyrimidin-4-yl)-amine; 30 (5-(2-Chloro-phenyl)-2H-pyrazol-3-yl]-thieno[3,2-d]pyrimidin-4-yl-amine; (1H-lndol-5-yl)-(6-pyridin-3-yl-thieno[3,2-d]pyrimidin-4-yl)-amine;(1H-lndol-5-yl)-{6-(3-methoxy-phenyl)-thieno[3,2-d]pyrirnidin-4-yl]-amine; {4-(4-(1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl}-phenyl}-methanol; (6-(3,4-Dimethoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; 35 [6-(4-Dimethylamino-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; (4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-phenyi-methanol; 4-(1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidine-6-carboxylic acid (2-dimethylaminoethyl)-amide; ( 1 H-l ndol-5-yl)-[6-(4-trifluoromethoxy-phenyl)-thieno(3,2-dlpyrimidin-4-yl]-amine; 40 ( 1 H-lndol-5-yl)-(6-(2-methoxy-phenyi)-thieno(312-d]pyrimidin-4-yl}-amine; 4-(4-( 1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-y0-phenol; -71- 011376 5 [6-(5-Diethoxymethyl-thiophen-2-yl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; 4-(1 H-lndol-5-ylamino)-thieno[3,2-d)pyrimidine-6-carboxylic acid (2-methoxy-ethyl)- amide; N-{4-[4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-N',N'-dimethyl-ethane- 1,2-diamine; 10 (1H-lndol-5-yl)-(6-{4-[(2-methoxy-ethylamino)-methyl]-phenyl}-thieno(3,2-d]pyrimidin-4- yl)-amine; (1H-lndol-5-yl)-{6-[2-(4-methyl-piperazin-1-yl)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}- amine; 4- (1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidine-6-carboxyiic acid propylamide; 15 2-(4-(4-( 1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyiamino}-ethanol; [6-(2,4-Dimethoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [6-(4-Diethylamino-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine; [6-(4-Ethoxy-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-(1H-indoI'5-yl)-amine; 3-(4-(4-( 1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzytamino}-propane-1,2-dioi; 20 (1H-lndol-5-yl)-(6-(4-propyiaminomethyl-phenyl)-thieno(3l2-d]pyrimidin-4-yl]-amine; (1H-lndol-5-yl)-(6-(4-((3-methoxy-propylamino)-methyl]-phenyl}-thieno{3,2-d]pyrimidin-4- yl)-amine; (6-(3-Fluoro-4-methoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol-5-yi)-amine; (1H-lndol-5-yl)-(6-(3-methylsulfanyl-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine; 25 (1 H-lndol-5-yl)-[6-(5-methyl-thiophen-2-yl)-thieno[3,2-d]pyrimidin-4-yl]-amine; (1H-lndol-5-yl)-(6-{4-[(2-piperazin-1-yl-ethylamino)-methyl]-phenyl}-thieno[3,2- d]pyrimidin-4-yl)-amine; (6-Benzo(1,3Jdioxol-5-yl-thieno[3,2-d]pyrimidin-4-yl)-(1H-indol-5-yl)-amine; {6-(4-(1-Ethoxy-ethoxy)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}-(1H-indol-5-yl)-amine; 30 (1 H-lndol-5-yl)-(6-(4-(2-pyrrolidin-1 -yl-ethoxy)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}-amine; (1H-lndol-5-yl)-(6-{4-(2-methoxy-ethoxy)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}-amine; (1H-lndol-5-yl)-{6-{4-((2-morpholin-4-yl-ethylamino)-methyt]-phenyl}-thieno(3,2- d]pyrimidin-4-yl)-amine; {6-[4-(2-Dimethylamino-ethoxy)-phenyl]-thieno[3,2-d]pyrimidin~4-yl}-(1H-indol-5-yl)- 35 amine; (1H-lndol-5-yl)-[6-(4-methylaminomethyl-phenyl)-ttiieno[3,2-d]pyrimidin-4-yl]-amine, 5- (6-Phenyl-thieno[3,2-d]pyrimidin~4-ylamino)-1,3-dihydro-indol-2-one;(1H-Benzotriazol-5-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylH4-(2H-tetrazol-5-yl}-phenyl]-amine; 40 N-{4-(4-{1 H-lndol-S-ytamino^thienofS^-dlpyrimidin-e-yll-benzylj-N'-methyl-ethane-l ,2- diamine; -72- 011376 5 (1 -Benzenesulfonyl-1 H-indol-5-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine; 3-{4-[4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-propan-1-ol; ( 1 H-l ndol-5-yl)-{6-[4-(4-methyl-piperazin-1 -ylmethyl)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}- amine; 2-{4-{4-{ 1 H-lndol-5-ylamino)-thieno[3,2-dJpyrimidin-6-yl]-benzylamino}-propane-1,3-diol; 10 2-((2-Hydroxy-ethyl)-{4-[4-(1 H-indol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}- amino)-ethanol; {5-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-thiophen-2-yl}-methanol; 2-(2-{4-{4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-ethoxy)- ethanol; 15 2-(2-{4-[4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-ylJ-benzylamino}-ethylamino)- éthanol; [6-(4-{[2-( 1 H-lmidazol-4-yl)-ethylamino]-methyl}-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-( 1H-indol-5-yl)-amine; (1H-lndol-5-yl)-{6-{4-{2-morpholin-4-yl-ethoxy)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}- 20 amine; 2- {4-(4-{1H-lndol-5-ylamino)-thieno[3l2-d]pyrimidin-6-yl]-phenoxy}-ethanol;[4-(2-Ethyl-oxazol-5-yl)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;N-(2-Methoxy-phenyl)-N'-(6-pheny1-thieno[3,2-d]pyrimidin-4-y1)-benzene-1,4-diamine;N-(4-Methoxy-phenyl)-N,-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine; 25 5-(4-(1 H-lndol-5-ylamino)-thieno{3,2-d]pyrimidin-6-yl]-thiophene-2-carbaldehyde; [5-(6-Phenyl-thieno{3,2-d]pyrimidin-4-ylamino)-1H-indol-2-yl]-methanol;(2-PhenyHH-indol-3-yl)-(6-phenyl-thieno(3,2-d]pyrimidin-4-yl)-amine;(9H-Carbazol-3-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(2-Methyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 30 (1 -Phenyl-ethyl)-(6-phenyl-thieno{3,2-d]pyrimidin-4-yl)-amine; (1H-lndol-5-yl)-(6-(4-{[(thiophen-2-ylmethyl)-amino]-methyI}-phenyl)-thieno(3,2- d]pyrimidin-4-yl]-amine; 3- {4-(4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-€-ylJ-benzylamino}-propionic acid methyl ester; 35 [6-(4-{[(Furan-2-ylmethyl)-amino]-methyl}-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-(1H-indol- 5-yl)-amine; 1-{3-{4-{4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-propyl)- pyrrolidin-2-one; N-^-^IH-Indol-S-ylaminoJ-thienoIS^-dlpyrimidin-e-ylJ-benzylJ-N'.N'-dimethyl- 40 propane-1,3-diamine; ( 1 H-lndoi-5-yl)-{6-(4-morpholin-4-ylmethyl-phenyl)-thieno(3,2-d]pyrimidin-4-yl]-amine; -73- 011376 5 (2-(4-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-acetylamino)- acetic acid ethyl ester; 1 .(4-(4.(4-( 1 h-I ndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzyl}-piperazin-1 -yl)-ethanone; (6-(4-((2,2-Diphenyl-ethylamino)-methyl]-phenyl}-thieno(3,2-d]pyrimidin-4-yl)-(1H-indol-10 5-yl)-amine; (1H-lndol-5-yl)-{6-[4-(2-methoxymethyl-pyrrolidin-1-ylmethyl)-phenyl]-thieno[3,2- d]pyrimidin-4-yi)-amine; N-(2-(4-(4-(1H-lndol-5-yiamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-ethyl)- acetamide; 15 [6-(4-Cyclopropylaminomethyl-phenyl)-thieno(3,2-dlpynmidin-4-yl]-(1 H-indol-5-yl)- amine; 2-{4-[4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzylamino}-butan-1-ol;2-((5-(4-(1 H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-th>ophen-2-ylmethyl}-amino)- éthanol; 20 (1H-lndol-5-yl)-(6-{4-((2-pyrrolidin-1-yl-ethylamino)-methyl]-ph?nyl}-thieno(3,2- d]pyrimidin-4-yl)-amine; (6-(4-(Benzylamino-methyl)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}-(1H-indol-5-yl)-amine; 1-{4-(4-(1H-lndol-5-ylamino)-thieno(3,2-d]pyrimidin-6-yl]-benzyl}-piperidine-4-carboxylic acid amide; 25 (1H-lndol-5-yl)-{6-[4-(pyrrolidin-3-ylaminomethyl)-phenyl]-thieno(3,2-d]pyrimidin-4-yl}- amine; (6-(4-((3-lmidazoH -yl-propylamino)-methyl]-phenyl}-thienoI3,2-d]pyrimidin-4-yl)-( 1H-indol-5-yl)-amine; N-{4-{4-( 1 H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-benzyl}-N', N’-dimethyl-hexane-30 ,1,6-diamine; (1-Allyl-1H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; ( 1 -Methyl-1 H-indol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(1H-lndol-5-ylH6-(4-{4-ptienyl-piperazin-1-ylmethyl)-phenyl]-thieno[3,2-d]pyrimidin-4-yl}- amine; 35 N-ÊS-^-OH-Indol-S-ylaminoJ-thienofS^-dlpyrimidin-e-yij-thiophen-Z-ylmethylj-N'.N'- dimethyl-ethane-1,2-diamine; N-{5-[4-(1H-lndol-5-ylamino)-thieno[3,2-d]pyrimidin-6-yl]-thiophen-2-ylmethyl}-N‘-methyl- ethane-1.2-diamine; (1H-lndol-5-yl)-(6-(5-I(2-methoxy-ethylamino)-methyl]-thiophen-2-yl}-thieno{3,2-40 d]pyrimidin-4-yl)-amine; -74- 0112764. A compound of claim 1 wherein said compound is a compound of formula 1wherein X1 is CH.
- 5-Methyl-1 -[4-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-1,2-dihydro-pyrazol-3- one; (2-Methyl-benzothiazol-6-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(S-Methylaminomethyl-IH-indoi-S-ylHe-phenyl-thienofS^-dlpyrimidin^-yO-amine;(4-Methoxy-2-methyl-phenyl)-(5-phenyl-thieno[3,2-d}pyrimidin-4-yl)-amine;[4-(4-Chloro-phenoxy)-phenyl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 40 -76- 011376 5 6-(6-Phenyl-thieno[3.2-d]pyrimidin-4-ylamino)-1 H-benzo(d][1,3]oxazine-2,4-dione;5. A compound of claim 1 wherein said compound is a compound of formula 1wherein R2 is phenyl optionally substituted by 1 to 5 R5 substituents.
- 6. A compound of claim 1 wherein said compound is a compound of formula 1wherein R2 is a group of the formulaor-69- 011276 5 wherein X2 is -S- or -N(R6)-, X3 is N or CH, the dashed line in formula 3 represents an optional double bond, and the above R2 groups of formulas 3 and 5 are optionally substituted by 1to 5 R5 substituents and the R2 groups of formulas 4 and 6 are optionally substituted by 1 to 3 R5substituents.
- 7. A compound of claim 6 wherein R2 is a group of formula 3 above wherein said 10 group is optionally substituted by 1 to 5 R5 substituents.
- 8. A compound of claim 1 wherein said compound is selected from the groupconsisting of: (3-Ethynyl-phenyl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine;(3-Ethynyl-phenyl)-[6-(4-methoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine ; 15 Benzo[b]thiophen-5-yl-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; (1H-lndol-5-yl)-[6-(4-methoxy-phenyl)-thieno[3,2-d]pyrimidin-4-yl]-amine; (1H-lndol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-(2-pyrrol-1-yl-phenyl)-amine; (5-Phenyl-1H-pyrazol-3-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 20 (5-Phenyl-1H-pyrazol-3-yl)-thieno[3,2-d]pyrimidin-4-yl-amine; ( 1 H-lndol-5-yl)-thieno[3,2-d]pyrimidin-4-yl-amine; N-(5-Phenyl)-1 -(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-1 H-[1,2,4]triazole-3,5-diamine; 3- [3-Phenyl-5-(6-phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-pyrazol-1-yl]-propionitrile·,(5-Furan-2-yl-2H-pyrazol-3-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 25 (6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-(5-thiophen-2-yl-2H-pyrazol-3-yl)-amine·, N-(6-Phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;N-[4-(6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-phenyl]-benzamide;N-Methyl-N'-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-benzene-1,4-diamine;(1H-lndazol-5-yl)-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 30 [5-(4-Chloro-phenyl)-2H-pyrazol-3-yl]-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; Benzothiazol-6-yl-(6-phenyl-thieno[3,2-d]pyrimidin-4-yl)-amine; 4- (6-Phenyl-thieno[3,2-d]pyrimidin-4-ylamino)-benzamide;
- 9. A compound according to claim 1 selected from the group consisting of -77- 011376 5 (2-(4-Fluoro-phenyl)-thieno(3,2-b]pyridin-7-yl]-(1H-indol-5-yl)-amine; (1H-lndol-5-yl)-(2-thiophen-2-yl-thieno(3,2-b]pyridin-7-yl)-amine; 4-(7-( 1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzaldehyde; (1H-lndol-5-yl)-(2-(4-methylsulfanyl-phenyl)-thieno(3,2-b]pyridin-7-yl]-amine; (1H-lndol-5-yl)-thieno(3,2-b]pyridin-7-yl-amine; 10 2-(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-ylJ-phenoxy}-ethanol; (2-(4-Dimethylamino-phenyl)-thieno(3,2-b]pyridin-7-ylJ-(1H-indol-5-yl)-amine; 4-(7-( 1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzoic acid methyl ester; (1 H-lndol-5-yl)-(2-thiophen-3-yl-thieno(3,2-b]pyridin-7-yl)-amine;(1H-lndol-5-yl)-(2-(4-((2-methoxy-ethyiamino)-methyl]-phenyl}-thieno(3,2-b]pyndin-7-yl)- 15 amine; Furan-2-yl-(4-(4-[7-(1H-indol-5-ylamino)-thieno(3l2-b]pyridin-2-yl]-benzyl}-piperazin-1- yl)-methanone; 4-(7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-phenol; 2-(2-(4-(7-(1 H-lndol-5-ylamino)-thieno(3,2-blpyridin-2-yl]-benzylamino}-ethoxy)-ethanol; 20 2-(4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-ethanol; N-{4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl(-benzyl}-N*,N'-dimethyV.hexane- 1,6-diamine; 2-({4-(7-(1H-lndol-5-ylamino)-thieno(3,2-b(pyridin-2-yl]-benzyl}-methyl-amino)-ethanol; (1H-lndol-5-yl)-(2-(4-[(2-piperazin-1-yl-ethylamino)-methyl]-phenyl}-thieno(3,2-b]pyridin- 7-yl)-amine; (2-(4-((3-lmidazol-1-yl-propylamino)-methyl]-phenyl}-thieno(3,2-b]pyridin-7-yl)-(1H-indol- 5-yl)-amine; 2-((2-Hydroxy-ethyl)-(4-{7-(1H-indol-5-ylamino)-thieno[3,2-b]pyrïdin-2-yl]-benzyl}-amino) éthanol; 30 (2-(4-Dimethylaminomethyl-phenyl)-thieno(3,2-b]pyridin-7-yl]-{ 1 H-indol-5-yl)-amine; N-(4-i7-(1H-lndol-5-ylaniino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-N,,N'-dimethyl-ethane- 1,2-diamine; (1-{4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-benzyl}-pyiTolidin-2-yl)-methanol;2-(4-(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-piperazin-1 -yl)-ethanol; 35 ( 1 H-lndol-5-yl)-(2-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-thieno(3,2-b]pyridin-7-yl}-amine; 1 -(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-piperidine-4-carboxylic acid amide; (4-(7-(1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-phenyl}-methanol; 2-(4-(7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-butan-1-ol; 40 N-(4-(7-( 1 H-Indol-S-ylaminoJ-thienolS^-bJpyridin^-yll-benzyiy-N'-methyl-ethane-l ,2- diamine; -78- 011376 5 (1H-lndol-5-yl)-(2-(4-morpholin-4-ylmethyl-phenyl)-thieno[3,2-bJpyridin-7-yl]-amine; 3-(4-(7-( 1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-propan-1-ol; 1- (3-(4-(7-( 1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-propyl)-pyrrolidin-2-one; (1H-lndol-5-yl)-{2-(4-(2-methoxy-ethoxy)-phenyl]-thieno(3,2-b]pyridin-7-yl}-amine; 10 2-(2-(4-(7-(1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-ethylamino)- éthanol; 3-(4-(7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-2,2-dimethyl-propan-1-ol; 3-(4-(7-( 1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-propane-1,2-diol; 15 [2-(4-{[2-(1 H-lmidazol-4-yl)-ethylamino]-methyl}-phenyl)-thieno[3,2-b]pyridin-7-yl]-(1 H- indol-5-yl)-amine; N-(2-{4-[7-(1H-lndol-5-ylamino)-thieno[3l2-b]pyridin-2-yl]-benzylamino}-ethyl)- acetamide; 2- {4-(7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-acetamide; 20 2-(4-(7-( 1H-lndol-5-ylamino)-thieno[3,2-bJpyridin-2-yl]-benzylamino}-propane-1,3-diol; N-(4-Methoxy-phenyl)-N'-[2-(3-nitro-phenyl)-thieno[3,2-b]pyridin-7-yl]-benzene-1,4- diamine; (7-Methoxy-1 H-indol-5-yl)-(2-phenyl-thieno(3,2-b]pyridin-7-yl)-amine; (1H-lndol-5-yl)-[2-(4-methylaminonrcethyl-phenyl)-thieno(3,2-b}pyridin-7-yl]-amine; 25 N-(4-[7-(1 H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2-diamine; {4-(7-(1 H-lndol-5-ylamino)-thieno{3,2-b]pyridin-2-yl]-benzylamino}-acetic acid methyl ester; N-^-P-OH-lndol-S-yiaminoi-thienoP^-blpyridin^-yll-benzyQ-N'.N'-dimethyl-propane- 1,3-diamine; 30 (1H-lndol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; (1H-lndol-5-yl)-(2-(4-[(2-morpholin-4-yl-ethylamino)-methyl]-phenyl}-thieno[3,2-b]pyridin- 7-yl)-amine; (1H-lndol-5-yl)-(2-[4-(pyrroltdin-3-ylaminomethyl)-phenyl]-thieno(3,2-b]pyridin-7-yl}- amine; 35 1 -(4-(4-(7-( 1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyt}-piperazin-1-yl)- ethanone; 1-(4-(7-(1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-pyrrolidine-2-carboxylicacid amide; N-(4-Methoxy-phenyl)-N'-(2-(6-methoxy-pyridin-3-yl)-thieno{3,2-b]pyridin-7-yl]-benzene-40 1,4-diamine; (1H-lndol-5-yl)-(2-pyridin-3-yi-thieno(3,2-b]pyridin-7-yl)-amine; -79- 5 4-{7-(1H-!ndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-but-3-yn-1-ol; N-(4-Methoxy-phenyl)-N'-(2-thiophen-2-yl-thieno[3,2-b]pyridin-7-yl)-benzene-1,4- diamine; N-(2-Hydroxy-ethyl)-4-(7-(1H-indol-5-ylamino)-thteno[3,2-b]pyridin-2-yl]-benzamide; N-(3-lmidazol-1-yl-propyl)-4-[7-(1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]- 10 benzamide; 3-{4-(4-{4-[7-(1H-lndol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-butyl)- piperazin-1-yl]-propan-1-ol; ( 1 K-lndol-5-yl)-[2-(4-{[4-(4-meîhyl-piperazin-1 -yl)-butylamino]-methyl}-phenyl)-thieno[3.2-b]pyridin-7-yl]-amine; 15 2-[4-(4-{4-[7-(1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-benzylamino}-butyl)- piperazin-1 -yf]-ethanol; 1- lmidazol-1-yt-3-{4-r7-(1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yi]-benzylamino}-propan-2-ol; 5-{4-[7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-pentan-1 -ol; 20 2-[2-{4-{4-[7-(1H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-piperazin-1-yl)- ethoxy]-ethanol·, (1H-lndo!-5-yl)-(2-{4-[(2-methylsijlfanyl-ethylamino)-methyl]-phenyl}-thieno[3,2-blpyridin 7-yl)-amine; 2- [(2-Hydroxy-ethyl)-(3-{4-{7-{1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-25 benzylamino}-propyl)-amino]-ethanol; N-(2-Amino-ethyl)-N'-{4-[7-(1H-indol-5-ylamino)-thieno[3,2-blpyridin-2-yl]-benzyl}- ethane-1.2-diamine; 2-(3-{4-[7-{1H-lndol-5-ylamino)-thieno(3.2-b]pyridin-2-yl]-benzylamino}-propylamino)- éthanol; 30 . N-{4-[7-(1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-hexane-1,6-diaminé; (2-Methyl-1H-indol-5-yl)-I2-{4-morpholin-4-ylmethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]- amine; 2-{4-[7-(2-Methyl-1 H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzylamino}-ethanol;(1H-lndol-5-yl)-[2-(6-methoxy-pyridin-3-yl)-thieno[3,2-b]pyridin-7-yl]-amine; 35 {5-[7-{ 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-2-yl}-methanor, N,N-Dimethyl-N’-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3.2-b]pyridin-2-yl]-benzyl}- propane-1,3-diamine; 2-{(2-Hydroxy-ethyl)-(3-{4-(7-(2-methyl-1H-indol-5-ylamino>-thieno[3>2-b]pyridin-2-yl]- benzylamino}-propyl)-amino}-ethanol; 40 2-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}-propane- 1.3-diol; -80- 5 3-{4-{7-(2-Methyl-1H-indol-5-ylamino)-thienol3,2-b]pyridin-2-yl]-benzyIamino}-propane- 1,2-diol; 1- (3-{4-[7-(2-Methyl-1H-indol-5-ylamino)-thieno(3l2-blpyridin-2-yl]-benzylamino}-propyl)-pyrrolidin-2-one; N-(2-Amino-ethyl)-N,-{4-p-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-10 benzyl}-ethane-1,2-diamine; 2- (2-{4-[7-(2-Methyl-1H-indol-5-ylamino}-thieno[3,2-b]pyridin-2-yf]-benzyfamino}-ethylamino)-ethanol; 3- {4-[7-(2-MethyH H-indol-5-ylamino)-thieno(3,2-blpyridin-2-yl]-benzylamino}-propan-1 -ol; 15 1-{4-[7-(2-MethyH H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-piperidine-4- carboxylic acid amide; 2-(244-[7-{2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzylamino}- ethoxy)-ethanol; 2- (Methyl-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-amino)- 20 éthanol; N-Methyl-N’-{4-[7-(2-methyl-1 H-indol-5-ylamino)-thieno{3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2-diamine; (1H-lndol-5-yl)-[2-(3-nitro-phenyl)-thieno[3,2-b]pyridin-7-yl]-amine; N-{4-[7-{2-MethyH H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2- 25 diamine; (2-Methyl-1H-indol-5-yl)-(2-{4-{(2-piperazin-1-yl-ethylamino)-methyl]-phenyl}-thieno(3l2- b]pyridin-7-yl)-amine; N,N-Dimethyl-N'-{4-[7-(2-methyl-1H-indol-5-ylamino}-thieno{3,2-b]pyridin-2-yl]-benzyl}-ethane-1,2-diamine; 30 2-{4-{7-{2-Methyl-1 H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl}-benzylamino}-butan-1-ol·, (2-Methyl-1H-indol-5-yl)-(2-{4-l(2-morpholin-4-yl-ethylamino)-methy0-phenyl}-thieno[3,2- b]pyridin-7-yl)-amine; (2-MethyHH-indol-5-ylH2-[4-(pyTOlidin-3-ylaminomethyl)-phenyl]-thieno(3.2-b]pyridin- 7-yl}-amine; 35 {6-(7-( 1 H-lndol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-3-yl}-methanol; {6-P-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-3-yl}-methanol; 3- [4-(4-{4-(7-(2-Methyl-1H-indol-5-ylamino)-thieno(3,2-b]pyridin-2-yl}-benzylamino}-butyl)-piperazin-1 -yl]-propan-1 -ol; 2-[4-(4-{4-{7-(2-Methyl-1H-indol-5-ylamino}-thiena[3,2-b]pyridin-2-yf}-benzylamino}-40 butyl)-piperazin-1 -yi]-ethanol; -81- οι un 5 (2-{4-[(3-lmidazol-1-yl-propylamino)-methyl]-phenyl}-thieno[3.2-b]pyridin-7-yl)-(2-methyl 1 H-indol-5-yl)-amine; 1- lmidazol-1-yl-3-{4-(7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-ylJ-benzylamino}-propan-2-ol; 2- [(2-Hydroxy-ethyl)-(4-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b}pyridin-2-yl]- 1Q benzylamino}-butyl)-amino}-ethanot; N,N-Diethyl-N‘-{4-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzyl}-propane-1,3-diamine; (2-(3-Amino-phenyl)-thieno[3>2-blpyridin-7-yl]-(1H-indol-5-yl)-amine; (2-Methyl-1H-indol-5-yl)-(2-{4-[(3-morphorm-4-yi-propylamino)-methyl]-phenyl}- 15 thieno[3,2-b]pyridin-7-yl)-amine; [2-(4-Dimethylaminomethyl-phenyl)-thieno[3,2-b]pyridin-7-yl]-(2-methyHH-indol-5-yl)- amine; 1- {5-(2-Pyridin-2-yl-thieno[3,2-b]pyridin-7-ylamino}-2,3-dihydro-indol-1-yl]-ethanone;(2,3-Dihydro*1H-indol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; 20 (1 H-Benzotriazol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; 5-(2-Phenyl-thieno[3.2-b]pyridin-7-ylamino)-1K-indole-3-carbaldehyde; (1K-lndazol-5-yl)-(2-pyridin-2-yl-thieno[3,2-b]pyridin-7-yl)-amine; (2-Methyl-1H-indol-5-yl)-(2-pyridin-2-yl-thieno(3,2-b]pyridin-7-yl)-amine; (1H-Benzoimidazol-5-yl)-(2-phenyl-thieno[3,2-b]pyridin-7-yl)-amine; 25 5-(2-Pyridin-2-yl-thieno[3,2-b]pyridin-7-ylamino)-1 H-indole-2-carboxylic acid dimethylamide; {5-[7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-pyridin-2-yl}-methanol; N-(3«lmidazol-1-yl-propyl)-6-[7-(1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]- nicotinamide; 30 N-(3-Hydroxy-propyl)-6-[7-(2-methyl-1H-indol-5-ytamino)-thieno[3,2-b]pyridin-2-yl]- nicotinamide; (2-(5-Amino-pyridin-2-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine; N-[2-{2-Hydroxy-ethoxy)-ethyl]-6-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin- 2-yl]-nicotinamide; 35 [2-(3-Methyl·3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-{2-methyl-1H-indol-5-yl)-amine; 2- {1 -Methyl-5-f7-(2-methyH H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-1 H-imidazol-2-yl}-propan-2-ol; [2-( 1 -Methyl-1 H-imidazol-2-yl)-thieno(3,2-blpyridin-7-yl]-(2-methyl-1 H-indol-5-yl)-amine;(2-Methyl-1H-indol-5-yl)-(2-thiazol-2-yl-thieno(3,2-b]pyridin-7-yl)-amine; 40 2-{2-[7-{2-Methyl-1H-indol-5-ylamino)-thier)0[3,2-b]pyridin-2-yl]-thiazol-5-yl}-propan-2-ol; 4-{7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-benzaldehyde; -82- 011376 5 and the pharmaceutically acceptable salts and hydrates thereof.
- 10. A compound of the formula 25 or 26or a pharmaceutically acceptable sait or hydrate thereof, wherein:wherein X1 is N or CH; 10 Z’ is halo and Z2 is -NR1R2; or Z1 is R11 and Z2 is halo; orZ1 and Z2 are each independently halo; R1 is H, Ο,-Οβ alkyl or -C(O)(C,-C6 alkyl); R2 is C6-C10 aryl or 5-13 membered heterocyclic, wherein said R2 groups are optionally15 substituted by 1 to 5 R5 substituents, each R3 is independently selected from H, -C(O)OR9, and C^Ce alkyl wherein said alkyl isoptionally substituted by 1 to 3 Rs groups; R4is R3.-OR9. or-NR’R10; each R5 is independently selected from halo, cyano, nitro, trifluoromethoxy,20 trifluoromethyl, azido, -C(O)R8, -C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7,-NR6R7, -OR9, -SO2NR8R7, CrC6 alkyl, -(CK2)jO(CH2)qNR8R7, -(CH2),O(CH2)qOR9, -(CH2),OR9,-SfO^CrCe alkyl). -(CH2),(C6-Cio aryl), -(CH2),(5-10 membered heterocyclic), -C(O)(CH2),(C6-C10 aryl), -(CH2),0(CH2))(C6-Cio aryl), -(CH2)tO(CH2)q(5-10 membered heterocyclic).-C(O)(CH2),(5-10 membered heterocyclic), -{CH2)jNR7(CH2)qNReR7, -(CH2)jNR7CH2C(O)NR6R7,25 -(CH2)jNR7(CH2)qNR9C(O)R8, -(CH2)jNR7(CH2),O(CH2)qOR9, -(CH2)jNR7(CH2)qS(O)j(C1-C6 alkyl),-(CH2)jNR7(CH2)tR6, -SO^CH^Ce-Cw aryl), and -SO2(CH2),(5-10 membered heterocyclic),wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6, q is an integerranging from 2 to 6, the -(CH2)q- and -(CH2)r moieties of the foregoing R5 groups optionallyinclude a carbon-carbon double or triple bond where t is an integer between 2 and 6, and the30 alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C(O)R8,-C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7, -(CH2),NR6R7, Ο,-Ce alkyl,-(CH2)t(Ce-C,o aryl), -(CH2),(5-10 membered heterocyclic), -(CH^OiCH^OR9, and -{CH2),OR9,wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6; 011 376 -83- 5 each R6 and R7 is independently selected from H, Ci-C6 alkyl, -(CH2),(C6-C,o aryl), -(CH2),(5-1O membered heterocyclic), -(CH2),O(CH2)qOR9, and -<CH2),OR9, wherein t is aninteger ranging from 0 to 6 and q is an integer ranging from 2 to 6, and the alkyl, aryl andheterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted by 1 to 3substituents independently selected from halo, cyano, nitro, trifluoromethyl, azido, -C{O)Ra, 10 -C(O)OR8, -CO(O)R8, -OC(O)OR8, -NR9C(O)R10, -C(O)NR9RW, -NR9R10, C,-C6 alkyl. -(CH2),(C6-C10 aryl), -(CH2),(5-10 membered heterocyclic), -(CH2)1O(CH2)qOR9, and -(CH2),OR9,wherein t is an integer ranging from 0 to 6 and q is an integer ranging from 2 to 6, with theproviso that where R6 and R7 are both attached to the same nitrogen, then R6 and R7 are notboth bonded to the nitrogen directly through an oxygen; 15 each R8 is independently selected from H, C,-Cw alkyl, -(CH2),(C6-C10 aryl), and -(CH2),(5-10 membered heterocyclic), wherein t is an integer ranging from 0 to 6; each R9 and R10 is independently selected from H and Ci-C6 alkyl; R” is H, Ci-C6 alkyl, -C(O)NR6R9, -C(O)(C6-C10 aryl). -(CHzMCg-Cw aryl), or -(CH2),(5-10 membered heterocyclic), wherein t is an integer ranging from 0 to 6, wherein said R11 groups, 20 other than H, are optionally substituted by tert-butyl-dimethyksilanyl and 1 to 3 R5 groups; and, R’2 is H. C,-C6 alkyl, -C(O)(C,-C6 alkoxy), -S(O)j(Ci-C6 alkyl), -SO2(CH2),(C6-C10 aryl), -(CH2),(C6-C10 aryl), -{CH2),(5-10 membered heterocyclic). -{CH2),O(CH2)qOR9, or -(CH2),OR9,wherein j is an integer ranging from 0 to 2, t is an integer ranging from 0 to 6 and q is an integerranging from 2 to 6. 25
- 11. A pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of a compound of daim 1 and apharmaceutically acceptable carrier.
- 12. The pharmaceutical composition of daim 11 wherein said hyperproliferativedisorder is cancer.
- 13. The pharmaceutical composition of claim 12 wherein said cancer is brain, lung, kidney, rénal, ovarian, squamous cell, bladder, gastric, pancreatic, breast, head, neck,oesophageal, gynecological, prostate, colorectal or thyroid cancer.
- 14. The pharmaceutical composition of daim 11 wherein said hyperproliferative. disorder is noncancerous.
- 15. The pharmaceutical composition of claim 14 wherein said disorder is a benign hyperplasia of the skin or prostate.
- 16. A pharmaceutical composition for the treatment of a hyperproliferative disorder ina mammal which comprises a therapeutically effective amount of a compound of daim 1 incombination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, 40 alkylating agents, anti-metabolites, intercalating antibiotics, enzymes, topoisomerase inhibitors. -84- 011376 ' 5 blologlcal response modifiera, anti-hormones, and antl-androgens, and a pharmaceutically acceptable carrier.
- 17. A pharmaceutical composition for the treatment of pancreatitis or kidneydisease irt a mammal which comprises a therapeutically effective amount of a compound ofdaim 1 and a pharmaceutically acceptable carrier. 10
- 18. A pharmaceutical composition for the blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of claim 1 and apharmaceutically acceptable carrier.
- 19. A pharmaceutical composition for treating a disease related tovasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective 15 amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 20. The pharmaceutical composition of claim 19 wherein said disease isselected from the group consisting of tumor angiogenesis, chronlc Inflammatory diseasesuch as rheumatoid arthritis, afherosclerosis, skin diseases such as psoriasis, excema, andscleroderma, diabètes, diabetic retinopathy, retinopathy of prematurity, age-related macular 20 degeneration, hemangioma, glioma, melanoma, Kaposî's sarcoma and ovarian, breast,lung, pancreatic, prostate, colon and epidermoid cancer.
- 21. The use of a compound of claim 1 for the manufacture of a médicamentfor treatment of a hyperproliferative disorder.
- 22. The use of claim 21, wherein said hyperproliferative disorder is cancer.
- 23. The use of claim 22 wherein said cancer is brain, lung, squamous cell, rénal, kidney. ovarian, bladder, gastric. pancreatic, breast. head, neck, oesophageal.prostate, colorectal, gynecological or thyroid cancer.
- 24. The use of daim 21 wherein said hyperproliferative disorder isnoncancerous.
- 25. The use of claim 24 wherein said disorder is a benign hyperplasia of the skin or prostate.
- 26. The use of a compound of claim 1 in combination with an anti-tumor agentselected from the group consisting of mitotic inhibitors, alkylating agents, antl-metabolites,intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors. enzymes. 35 topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgensfor the manufacture of a médicament for treating a hyperproliferative disorder.
- 27. The use of a compound of claim 1 for the manufacture of a médicamentfor treating pancreatitis or kidney disease.
- 28. The use of a compound of claim 1 for the manufacture of a médicament40 for treatment of blastocyte implantation. -85- 011376 10
- 29. Xrhe use of a compound of clalm 1 for the manufacture or a médicamentfor treating a'aisease related ta vasculogenesis or angiogenesis.
- 30. The use of daim 29 wherein said disease is selected from the groupconsisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoidarthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma,diabètes, diabetic retinopathy,' retinopathy of prematurity, age-relatad maculardegeneration, hemangioma, glioma, melanoma, Kaposi’s sarcoma and ovarian, breast,lung, pancreatic, prostate, "colon âpd epidermoid cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6509797P | 1997-11-11 | 1997-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA11376A true OA11376A (en) | 2004-01-28 |
Family
ID=22060322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200000133A OA11376A (en) | 1997-11-11 | 2000-05-05 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. |
Country Status (37)
Country | Link |
---|---|
US (1) | US6492383B1 (fr) |
EP (1) | EP1028964A1 (fr) |
JP (1) | JP2001522853A (fr) |
KR (1) | KR100446363B1 (fr) |
CN (2) | CN101328186A (fr) |
AP (1) | AP976A (fr) |
AR (1) | AR018517A1 (fr) |
AU (1) | AU9454198A (fr) |
BG (1) | BG65180B1 (fr) |
BR (1) | BR9814018A (fr) |
CA (1) | CA2309690A1 (fr) |
CO (1) | CO4990956A1 (fr) |
CZ (1) | CZ20001709A3 (fr) |
DZ (1) | DZ2646A1 (fr) |
EA (1) | EA005889B1 (fr) |
GT (1) | GT199800180A (fr) |
HN (1) | HN1998000168A (fr) |
HR (1) | HRP20000286A2 (fr) |
HU (1) | HUP0100287A3 (fr) |
ID (1) | ID23978A (fr) |
IL (1) | IL135636A0 (fr) |
IS (1) | IS5464A (fr) |
MA (1) | MA24694A1 (fr) |
MY (1) | MY132073A (fr) |
NO (1) | NO20002162L (fr) |
NZ (1) | NZ520093A (fr) |
OA (1) | OA11376A (fr) |
PA (1) | PA8462401A1 (fr) |
PE (1) | PE129099A1 (fr) |
PL (1) | PL340589A1 (fr) |
SK (1) | SK6652000A3 (fr) |
TN (1) | TNSN98203A1 (fr) |
TW (1) | TW593321B (fr) |
UA (1) | UA72881C2 (fr) |
UY (2) | UY25238A1 (fr) |
WO (1) | WO1999024440A1 (fr) |
ZA (1) | ZA9810253B (fr) |
Families Citing this family (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
EP1006113A1 (fr) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
GB9918057D0 (en) * | 1999-07-30 | 1999-10-06 | Univ Bristol | Therapeutic agents |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
GB0010757D0 (en) * | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
EP1287001B1 (fr) | 2000-06-06 | 2004-09-29 | Pfizer Products Inc. | Derives de thiophene utilises comme agents anticancereux |
WO2002012227A2 (fr) * | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Composes chimiques |
AU2001293817A1 (en) | 2000-09-20 | 2002-04-02 | Merck Patent Gmbh | 4-amino-quinazolines |
US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
KR20020051675A (ko) * | 2000-12-23 | 2002-06-29 | 이상남 | 4-페닐아미노티에노 [3,2-디] 피리미딘 유도체 및 이의제조방법 |
CA2433800C (fr) | 2001-01-05 | 2016-09-13 | Pfizer Inc. | Anticorps anti-recepteur du facteur de croissance insulinoide i |
DE60212487T2 (de) * | 2001-04-13 | 2006-12-21 | Pfizer Products Inc., Groton | Bizyklisch substituierte 4-Aminopyridopyrimidinderivate |
WO2003000194A2 (fr) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
EP1463507A1 (fr) * | 2001-12-19 | 2004-10-06 | SmithKline Beecham Corporation | Composes de thienopyrimidine en tant qu'inhibiteurs de la proteine tyrosine kinase |
AU2002364211A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
US20040014755A1 (en) | 2002-01-10 | 2004-01-22 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
ES2298497T3 (es) | 2002-01-23 | 2008-05-16 | Bayer Pharmaceuticals Corporation | Inhibidores de quinasa rho. |
WO2003062225A1 (fr) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Derives pyrimidine en tant qu'inhibiteurs de kinase rho |
WO2003064428A1 (fr) * | 2002-01-29 | 2003-08-07 | H. Lundbeck A/S | Furano- et thienopyrimidines en tant qu'inhibiteurs de la neurokinase |
AU2003216322A1 (en) | 2002-02-15 | 2003-09-09 | Rigel Pharmaceuticals, Inc. | Inhibitors of tubulin polymerization |
US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
ATE323702T1 (de) | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
US7276519B2 (en) | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
PL377713A1 (pl) | 2002-12-19 | 2006-02-06 | Pfizer Inc. | Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu |
AU2003285614B2 (en) | 2002-12-20 | 2009-05-14 | Pfizer Products, Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
AP2114A (en) | 2003-02-26 | 2010-03-04 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
WO2005010008A1 (fr) * | 2003-07-24 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Composes tetrahydrobenzothienopyrimidinamine a substitution utiles pour le traitement de troubles hyper-proliferatifs |
WO2005013982A1 (fr) * | 2003-08-06 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Composes d'aminotriazole utiles en tant qu'inhibiteurs des proteines kinases |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
WO2005016346A1 (fr) | 2003-08-14 | 2005-02-24 | Array Biopharma Inc. | Analogues de quinazoline comme inhibiteurs du recepteur de la tyrosine kinase |
ATE412655T1 (de) | 2003-08-29 | 2008-11-15 | Pfizer | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
GEP20084572B (en) | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
CA2553513A1 (fr) * | 2004-01-22 | 2005-08-04 | Altana Pharma Ag | N-4-(6-(hetero)aryle-pyrimidine-4-ylaminophenyle)-bezenesulfonamides en tant qu'inhibiteurs de kinase |
BRPI0511512A (pt) * | 2004-05-27 | 2007-12-26 | Pfizer Prod Inc | derivados pirrolpirimidina úteis no tratamento do cáncer |
GB0412467D0 (en) * | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7879853B2 (en) | 2004-06-28 | 2011-02-01 | Bayer Schering Pharma Ag | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
RU2007107167A (ru) | 2004-07-30 | 2008-09-10 | Метилджин, Инк. (Ca) | Ингибиторы передачи сигнала рецептора vegf и рецептора hgf |
DK1786785T3 (da) | 2004-08-26 | 2010-05-31 | Pfizer | Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
RU2007119637A (ru) * | 2004-10-28 | 2008-12-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве модуляторов hedgehog-пути |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
CN101107227B (zh) * | 2005-01-19 | 2010-09-22 | 霍夫曼-拉罗奇有限公司 | 5-氨基吲哚衍生物 |
EP1861715B1 (fr) | 2005-03-16 | 2010-08-11 | OSI Pharmaceuticals, Inc. | Biomarqueurs predictifs de reponse anticancereuse a des inhibiteurs de kinase de recepteur de facteur de croissance epidermique |
BRPI0609655A2 (pt) | 2005-03-31 | 2010-03-16 | Agensys Inc | anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b |
CA2604357C (fr) | 2005-04-26 | 2012-01-17 | Pfizer Inc. | Anticorps de la p-cadherine |
WO2008041053A2 (fr) * | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibiteurs de la signalisation du récepteur vegf et du récepteur hgf |
CN101248080B (zh) * | 2005-05-20 | 2012-09-05 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
WO2006136402A1 (fr) * | 2005-06-22 | 2006-12-28 | Develogen Aktiengesellschaft | Thiénopyrimidines pour compositions pharmaceutiques |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
AR055625A1 (es) * | 2005-09-02 | 2007-08-29 | Pfizer | Procedimientos mejorados para preparar derivados de tienopiridinas heteroaril amida benzocondensados |
UY29783A1 (es) | 2005-09-07 | 2007-04-30 | Pfizer | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
PE20070619A1 (es) * | 2005-09-27 | 2007-07-02 | Wyeth Corp | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA |
WO2007056214A2 (fr) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc | N-alkyl-n-aryl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation associee |
WO2007056208A2 (fr) * | 2005-11-02 | 2007-05-18 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation de ceux-ci |
US20070099877A1 (en) * | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1971601B1 (fr) | 2005-11-15 | 2009-10-21 | Array Biopharma Inc. | Derivés de la n4-phényl-quinazoline-4-amine et composés similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives |
WO2008063202A2 (fr) * | 2006-01-30 | 2008-05-29 | Array Biopharma Inc. | Composés hétérobicycliques de thiophène et leurs méthodes d'utilisation |
US20080064718A1 (en) * | 2006-03-22 | 2008-03-13 | Saavedra Oscar M | Inhibitors of protein tyrosine kinase activity |
JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
EA200802118A1 (ru) | 2006-04-07 | 2009-04-28 | Девелоджен Ациенгезельшафт | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях |
RS20080525A (en) | 2006-05-09 | 2009-09-08 | Pfizer Products Inc., | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
EP1889847A1 (fr) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Dérivés de pyrrolopyrimidine pour applications pharmaceutiques |
BRPI0718029A2 (pt) | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
CL2007003520A1 (es) | 2006-12-07 | 2008-08-22 | Piramed Ltd Genentech Inc | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. |
WO2008082839A2 (fr) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Inhibiteurs de la pim kinase comme agents chimiothérapeutiques destinés à lutter contre le cancer |
EP2476679B1 (fr) * | 2006-12-29 | 2015-10-14 | Rigel Pharmaceuticals, Inc. | Triazoles substitués utilisés comme inhibiteurs AXL |
US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
JP5539190B2 (ja) * | 2007-06-12 | 2014-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾロピリミジン類及びホスファチジルイノシトール−3キナーゼのインヒビターとしてのそれらの使用 |
EP2014662A1 (fr) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine en tant que modulateurs du récepteur EP2 |
EP2014663A1 (fr) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine en tant que modulateurs du récepteur EP2 |
CN101932587A (zh) * | 2007-09-24 | 2010-12-29 | 吉宁特有限公司 | 噻唑并嘧啶pi3k抑制剂化合物及使用方法 |
NZ592534A (en) * | 2007-10-18 | 2013-03-28 | Boehringer Ingelheim Int | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
BRPI0819328A8 (pt) * | 2007-11-15 | 2016-02-10 | Boehringer Ingelheim Int | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos |
CA2707046A1 (fr) | 2007-11-28 | 2009-06-11 | Nathanael S. Gray | Inhibiteurs myristate a petites molecules de bcr-abl et procedes d'utilisation |
EA018133B1 (ru) * | 2008-01-11 | 2013-05-30 | Гленмарк Фармасьютикалс, С.А. | Конденсированные пиримидиновые производные как модуляторы trpv3 |
US8211897B2 (en) | 2008-02-07 | 2012-07-03 | Virobay, Inc. | Inhibitors of cathepsin B |
NZ589336A (en) | 2008-03-05 | 2011-12-22 | Methylgene Inc | Pyridine derivatives as inhibitors of protein tyrosine kinase activity |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
WO2010023181A1 (fr) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thiénopyrimidines pour compositions pharmaceutiques |
US8476410B2 (en) | 2008-10-16 | 2013-07-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof |
KR101126736B1 (ko) * | 2008-11-27 | 2012-04-12 | 주식회사 레고켐 바이오사이언스 | 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물 |
AU2010210986A1 (en) | 2009-02-09 | 2011-08-25 | Supergen, Inc. | Pyrrolopyrimidinyl Axl kinase inhibitors |
EP2400985A2 (fr) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Thérapie anti-cancer combinée |
EP2400990A2 (fr) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo |
EP2401614A1 (fr) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
WO2010099138A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用 |
KR20130026364A (ko) * | 2009-05-27 | 2013-03-13 | 제넨테크, 인크. | P110 델타에 대해 선택적인 비시클릭 피리미딘 pi3k 억제제 화합물 및 사용 방법 |
SG182247A1 (en) * | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
KR20120106935A (ko) | 2009-07-13 | 2012-09-27 | 제넨테크, 인크. | 암의 치료를 위한 진단 방법 및 조성물 |
US20120128670A1 (en) | 2009-07-31 | 2012-05-24 | OSI Pharmaceuticals, LLC | mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY |
WO2011027249A2 (fr) | 2009-09-01 | 2011-03-10 | Pfizer Inc. | Dérivés de benzimidazole |
US20110064670A1 (en) | 2009-09-11 | 2011-03-17 | Genentech, Inc. | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
CA2772670A1 (fr) | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methodes et compositions utilisees a des fins de diagnostic chez les patients atteints du cancer |
WO2011073521A1 (fr) | 2009-12-15 | 2011-06-23 | Petri Salven | Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations |
ES2753748T3 (es) | 2010-02-12 | 2020-04-14 | Pfizer | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
MX2012009851A (es) | 2010-02-26 | 2012-09-12 | Boehringer Ingelheim Int | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas. |
ES2547905T3 (es) | 2010-02-26 | 2015-10-09 | Evotec International Gmbh | 4-[Cicloalquiloxi(hetero)arilamino]-tieno[2,3-d]pirimidinas que tienen actividad inhibidora de la Mnk1/Mnk2 para composiciones farmacéuticas |
CA2783656A1 (fr) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Marqueurs biologiques predictifs d'une reponse anticancereuse aux inhibiteurs de kinase du recepteur du facteur de croissance insulinique 1 |
EP2542893A2 (fr) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 |
BR112012026470A2 (pt) | 2010-04-16 | 2016-08-09 | Genentech Inc | método para prever a sensibilidade de crescimento de células tumorais e para tratar um tumor em um paciente |
CN102250112A (zh) * | 2010-05-18 | 2011-11-23 | 上海再启生物技术有限公司 | 7-溴-4-氨基噻吩并嘧啶的制备方法 |
WO2011149126A1 (fr) * | 2010-05-26 | 2011-12-01 | 한국과학기술연구원 | Composition pharmaceutique comprenant un composé anti-inflammatoire présentant une fonction d'inhibition de la tyrosine kinase |
ES2647586T3 (es) * | 2010-05-26 | 2017-12-22 | Korea Institute Of Science And Technology | Compuesto antiinflamatorio que tiene actividad inhibidora contra múltiples tirosina cinasas, y composición farmacéutica que contiene el mismo |
WO2011153224A2 (fr) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Procédés diagnostiques et compositions de traitement du cancer |
CN103068851B (zh) | 2010-06-16 | 2015-03-11 | 高等教育联邦***-匹兹堡大学 | 内质蛋白的抗体及其用途 |
US20130225581A1 (en) | 2010-07-16 | 2013-08-29 | Kyowa Hakko Kirin Co., Ltd | Nitrogen-containing aromatic heterocyclic derivative |
KR20130126576A (ko) | 2010-07-19 | 2013-11-20 | 에프. 호프만-라 로슈 아게 | 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법 |
CN103180737A (zh) | 2010-07-19 | 2013-06-26 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
WO2012012750A1 (fr) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | Inhibiteurs anti-despr comme agents thérapeutiques pour l'inhibition de l'angiogenèse pathologique et de l'invasivité des cellules tumorales et pour l'imagerie moléculaire et l'administration ciblée |
EP3590925B1 (fr) | 2010-09-17 | 2022-03-30 | Purdue Pharma L.P. | Composés de pyridine et ses utilisations |
WO2012042421A1 (fr) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Procédé de traitement de la croissance cellulaire anormale |
WO2012052948A1 (fr) | 2010-10-20 | 2012-04-26 | Pfizer Inc. | Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened |
WO2012088254A1 (fr) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Polythérapie par inducteur et inhibiteur d'autophagie pour le traitement de néoplasmes |
JP5813785B2 (ja) | 2011-02-04 | 2015-11-17 | デュケイン ユニバーシティー オブ ザ ホリー スピリット | 抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法 |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
WO2012149014A1 (fr) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
EP3812387A1 (fr) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Inhibiteurs de protéine kinase hétérocycliques |
CA2847540C (fr) | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Derives de pyrrolopyrimidine et de purine |
EP3275902A1 (fr) | 2011-10-04 | 2018-01-31 | IGEM Therapeutics Limited | Anticorps ige anti-hmw-maa |
CN103087077B (zh) * | 2011-11-03 | 2016-05-18 | 上海希迈医药科技有限公司 | 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用 |
AU2012335247A1 (en) | 2011-11-08 | 2014-05-29 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-M-CSF antibodies |
CA2860548A1 (fr) * | 2012-01-10 | 2013-07-18 | Shaoqing Chen | Composes de thienopyrimidine |
FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
CN103360407B (zh) * | 2012-04-10 | 2016-06-22 | 上海希迈医药科技有限公司 | 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用 |
CN103664991B (zh) * | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
EP2909181B1 (fr) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Modulateurs de pkm2 et procédés pour les utiliser |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
WO2014130923A2 (fr) | 2013-02-25 | 2014-08-28 | Genentech, Inc. | Procédés et compositions pour détecter et traiter un mutant d'akt résistant aux médicaments |
EP2970205B1 (fr) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
TW201534597A (zh) | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
WO2015051302A1 (fr) | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions et procédés de traitement de cancers |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
PT3126528T (pt) | 2014-04-04 | 2021-09-09 | Crown Bioscience Inc Taicang | Métodos para determinar a responsividade a inibidores de mek/erk |
WO2015155624A1 (fr) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dérivés de dihydropyrrolopyrimidine |
MX2016014143A (es) | 2014-04-30 | 2017-02-15 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo. |
WO2016001789A1 (fr) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer |
JP2017520612A (ja) * | 2014-07-16 | 2017-07-27 | ノボジェン リミティッド | 抗がん剤としての官能化され置換されたインドール |
CN106999578B (zh) | 2014-07-31 | 2022-03-04 | 美国政府(由卫生和人类服务部的部长所代表) | 针对epha4的人类单克隆抗体和其用途 |
JP6621477B2 (ja) | 2014-12-18 | 2019-12-18 | ファイザー・インク | ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用 |
KR20180018507A (ko) | 2015-04-20 | 2018-02-21 | 톨레로 파마수티컬스, 인크. | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 |
WO2016178876A2 (fr) | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer |
MX2017014645A (es) | 2015-05-18 | 2018-01-23 | Tolero Pharmaceuticals Inc | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. |
WO2017009751A1 (fr) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Dérivés de pyrimidine |
WO2017024073A1 (fr) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Thérapies combinatoires pour le traitement du cancer |
KR20180100125A (ko) | 2015-12-03 | 2018-09-07 | 아지오스 파마슈티컬스 아이엔씨. | Mtap 널 암을 치료하기 위한 mat2a 억제제 |
SG11201804901WA (en) | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
EP3426653B1 (fr) * | 2016-03-11 | 2021-12-15 | AC Immune SA | Composes bicycliques pour le diagnostic et le traitement |
CN107652273B (zh) * | 2016-07-26 | 2020-05-01 | 沈阳药科大学 | 嘧啶类衍生物及其制备方法和应用 |
WO2018094275A1 (fr) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases |
CN110234659A (zh) | 2016-12-19 | 2019-09-13 | 特雷罗药物股份有限公司 | 用于敏感性分析的分析肽和方法 |
SG11201911929XA (en) | 2017-06-21 | 2020-01-30 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
CA3119807A1 (fr) | 2018-12-04 | 2020-06-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Inhibiteurs de cdk9 et leurs polymorphes destines a etre utilises en tant qu'agents pour le traitement du cancer |
TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
CA3127502A1 (fr) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprenant des inhibiteurs de proteine kinase heterocycliques |
US20220056043A1 (en) * | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
WO2020180768A1 (fr) * | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Composés hétéroaryle bicycliques et leurs utilisations |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
KR20210141621A (ko) | 2019-03-22 | 2021-11-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법 |
CN114269753B (zh) * | 2019-09-29 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 一种含氮并环类化合物,包含其的药物组合物,其制备方法及其用途 |
KR20220113700A (ko) * | 2019-12-12 | 2022-08-16 | 피티씨 테라퓨틱스, 인크. | 가족성 자율신경실조증 치료를 위한 화합물 |
WO2021155006A1 (fr) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations |
CN115746017A (zh) * | 2022-11-30 | 2023-03-07 | 英维沃化工科技(广州)有限公司 | 一种噻吩并嘧啶类化合物及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3277623D1 (en) * | 1981-07-31 | 1987-12-17 | Sloan Kettering Inst Cancer | Anti-leukemic beta-glycosyl c-nucleosides |
US5124331A (en) * | 1988-03-02 | 1992-06-23 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno[2,3-d]pyrimidine compounds and their pharmaceutical use |
CA2039411A1 (fr) | 1990-03-30 | 1991-10-01 | Ronnie Gerald Edie | Derives de la thienopyrimidine |
US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
CA2129337A1 (fr) * | 1992-02-19 | 1993-09-02 | Jotham W. Coe | Composes heterocycliques pour ameliorer l'activite antitumorale |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
JP3290666B2 (ja) * | 1995-06-07 | 2002-06-10 | ファイザー・インコーポレーテッド | 複素環式の縮合環ピリミジン誘導体 |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
ES2200039T3 (es) | 1995-12-08 | 2004-03-01 | Pfizer Inc. | Derivados heterociclicos sustituidos como antagonistas de crf. |
KR19990067390A (ko) | 1996-02-07 | 1999-08-16 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 티오페노피리미딘 |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
-
1998
- 1998-10-22 SK SK665-2000A patent/SK6652000A3/sk unknown
- 1998-10-22 BR BR9814018-3A patent/BR9814018A/pt not_active Application Discontinuation
- 1998-10-22 AU AU94541/98A patent/AU9454198A/en not_active Abandoned
- 1998-10-22 CA CA002309690A patent/CA2309690A1/fr not_active Abandoned
- 1998-10-22 UA UA2000042376A patent/UA72881C2/uk unknown
- 1998-10-22 EA EA200000391A patent/EA005889B1/ru unknown
- 1998-10-22 CN CNA2008101000200A patent/CN101328186A/zh active Pending
- 1998-10-22 JP JP2000520449A patent/JP2001522853A/ja active Pending
- 1998-10-22 CN CN98811858A patent/CN1280580A/zh active Pending
- 1998-10-22 CZ CZ20001709A patent/CZ20001709A3/cs unknown
- 1998-10-22 WO PCT/IB1998/001691 patent/WO1999024440A1/fr active IP Right Grant
- 1998-10-22 KR KR10-2000-7005010A patent/KR100446363B1/ko not_active IP Right Cessation
- 1998-10-22 HU HU0100287A patent/HUP0100287A3/hu unknown
- 1998-10-22 EP EP98947716A patent/EP1028964A1/fr not_active Withdrawn
- 1998-10-22 IL IL13563698A patent/IL135636A0/xx unknown
- 1998-10-22 NZ NZ520093A patent/NZ520093A/en unknown
- 1998-10-22 ID IDW20000864A patent/ID23978A/id unknown
- 1998-10-22 PL PL98340589A patent/PL340589A1/xx not_active Application Discontinuation
- 1998-10-26 HN HN1998000168A patent/HN1998000168A/es unknown
- 1998-10-29 PA PA19988462401A patent/PA8462401A1/es unknown
- 1998-11-05 AP APAP/P/1998/001389A patent/AP976A/en active
- 1998-11-06 PE PE1998001069A patent/PE129099A1/es not_active Application Discontinuation
- 1998-11-06 TW TW087118534A patent/TW593321B/zh not_active IP Right Cessation
- 1998-11-09 UY UY25238A patent/UY25238A1/es unknown
- 1998-11-09 MY MYPI98005088A patent/MY132073A/en unknown
- 1998-11-09 GT GT199800180A patent/GT199800180A/es unknown
- 1998-11-09 AR ARP980105653A patent/AR018517A1/es not_active Application Discontinuation
- 1998-11-10 DZ DZ980256A patent/DZ2646A1/fr active
- 1998-11-10 MA MA25338A patent/MA24694A1/fr unknown
- 1998-11-10 ZA ZA9810253A patent/ZA9810253B/xx unknown
- 1998-11-10 TN TNTNSN98203A patent/TNSN98203A1/fr unknown
- 1998-11-11 CO CO98066593A patent/CO4990956A1/es unknown
-
1999
- 1999-01-11 UY UY25344A patent/UY25344A1/es not_active IP Right Cessation
-
2000
- 2000-02-10 US US09/502,129 patent/US6492383B1/en not_active Expired - Fee Related
- 2000-04-19 IS IS5464A patent/IS5464A/is unknown
- 2000-04-27 NO NO20002162A patent/NO20002162L/no not_active Application Discontinuation
- 2000-05-05 OA OA1200000133A patent/OA11376A/en unknown
- 2000-05-09 BG BG104412A patent/BG65180B1/bg unknown
- 2000-05-10 HR HR20000286A patent/HRP20000286A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA11376A (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents. | |
KR101483215B1 (ko) | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 | |
US6413971B1 (en) | Fused bicyclic pyrimidine derivatives | |
EP2491043B1 (fr) | COMPOSÉS THIÉNO[3,2-D]PYRIMIDINES SUBSTITUÉS DANS LES POSITIONS 2 ET 7 EN TANT QU'INHIBITEURS DE PROTÉINE KINASE& xA; | |
JP4845736B2 (ja) | プロテインキナーゼ阻害剤 | |
US6995171B2 (en) | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | |
JP5070058B2 (ja) | 過増殖性疾患の処置のための上皮増殖因子受容体(egfrs)のチロシンキナーゼ活性のインヒビターとしてのベンゾチエノ’2,3−d!ピリミジン化合物 | |
JP2003535867A (ja) | 抗癌剤として有用なチオフェン誘導体 | |
JP2013523711A (ja) | アデノシンa2a受容体拮抗薬としての4−アミノピリミジン誘導体 | |
WO1996040142A1 (fr) | Derives de pyrimidine heterocycliques a noyaux condenses | |
OA12916A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents. | |
US20020004511A1 (en) | Thiophene derivatives useful as anticancer agents | |
US20030162795A1 (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | |
AU2002301080B2 (en) | Thienopyrimidine and Thienopyridine Derivatives Useful as Anticancer Agents | |
MXPA00004491A (en) | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |